NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Price, News & Analysis $1.11 +0.02 (+1.83%) (As of 08:54 AM ET) Add Compare Share Share Today's Range$1.11▼$1.1150-Day Range$1.03▼$1.7252-Week Range$0.62▼$2.31Volume416 shsAverage Volume1.39 million shsMarket Capitalization$139.59 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Atossa Therapeutics alerts: Email Address Atossa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside418.0% Upside$5.75 Price TargetShort InterestBearish8.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$44,250 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.08 out of 5 starsMedical Sector735th out of 879 stocksPharmaceutical Preparations Industry343rd out of 417 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Atossa Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.66% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Atossa Therapeutics has recently decreased by 2.94%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Atossa Therapeutics this week, compared to 2 articles on an average week.Search Interest14 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows7 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,250.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions.Read more about Atossa Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atossa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.See his shocking evidence in this new report About Atossa Therapeutics Stock (NASDAQ:ATOS)Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesJuly 3, 2024 | investorplace.com3 Penny Stock Moonshots with 300%+ Upside Potential by 2025July 2, 2024 | proactiveinvestors.comAtossa Therapeutics names Heather Rees as CFOJuly 8, 2024 | The Freeport Society (Ad)Biden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.July 2, 2024 | globenewswire.comAtossa Therapeutics Appoints Heather Rees as Chief Financial OfficerJune 29, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Earns "Buy" Rating from HC WainwrightJune 28, 2024 | globenewswire.comAtossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerJune 17, 2024 | globenewswire.comAtossa Set to Join Russell 3000® Index Effective June 28, 2024June 7, 2024 | investorplace.comMeme Mania Meets Medicine: 3 Biotech Stocks Primed to SoarJuly 8, 2024 | The Freeport Society (Ad)Biden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.June 5, 2024 | globenewswire.comAtossa to Present at the Sidoti Small-Cap Investor ConferenceMay 28, 2024 | globenewswire.comAtossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelMay 20, 2024 | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 17, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 15, 2024 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | proactiveinvestors.comAtossa Therapeutics gives final dose in breast cancer prevention studyMay 15, 2024 | globenewswire.comAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialMay 15, 2024 | markets.businessinsider.comAtossa Therapeutics’ Endoxifen Shows Promising Phase 2 Results, Secures Buy RatingMay 13, 2024 | msn.comAtossa Therapeutics files for $100M mixed shelf offeringSee More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/08/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees12Year Founded2009Price Target and Rating Average Stock Price Target$5.75 High Stock Price Target$6.25 Low Stock Price Target$5.00 Potential Upside/Downside+418.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.79% Return on Assets-31.25% Debt Debt-to-Equity RatioN/A Current Ratio16.34 Quick Ratio16.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.52Miscellaneous Outstanding Shares125,760,000Free Float116,199,000Market Cap$139.59 million OptionableOptionable Beta1.20 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 73)M.D., Ph.D., Chairman, CEO & President Comp: $1.21MMs. Heather Rees CPA (Age 51)Senior VP of Finance & Principal Accounting Officer Comp: $520.64kMs. Delly Behen P.H.R.Senior Vice President of Administration & HRMr. Eric Van ZantenVice President of Investor & Public RelationsDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerKey CompetitorsAB Corporate Bond ETFNASDAQ:EYEGJaguar HealthNASDAQ:JAGXTetraphase PharmaceuticalsNASDAQ:TTPHOlema PharmaceuticalsNASDAQ:OLMAArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsCetera Advisors LLCBought 39,898 shares on 5/24/2024Ownership: 0.032%Virtu Financial LLCBought 83,941 shares on 5/20/2024Ownership: 0.067%Vanguard Group Inc.Bought 78,269 shares on 5/10/2024Ownership: 4.592%PFG Investments LLCBought 23,650 shares on 4/22/2024Ownership: 0.019%Jonathan FinnBought 25,000 shares on 4/10/2024Total: $44,250.00 ($1.77/share)View All Insider TransactionsView All Institutional Transactions ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Therapeutics' stock was trading at $0.88 at the start of the year. Since then, ATOS stock has increased by 26.1% and is now trading at $1.11. View the best growth stocks for 2024 here. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. When did Atossa Therapeutics' stock split? Atossa Therapeutics's stock reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD) and Biopharmx (BPMX). This page (NASDAQ:ATOS) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
